CHROMOCELL THERAPEUTICS CORPORATION
NYSE: CHRO (Channel Therapeutics Corporatio)
Last update: 2 days ago, 10:22PM1.36
-0.01 (-0.73%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Channel Therapeutics Corporatio | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | -0.38 |
|
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 58.22% |
| % Held by Institutions | 12.68% |
| Date | Type | Details |
|---|---|---|
| 17 Apr 2025 | Announcement | Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |